Literature DB >> 10575060

The therapeutic gap--compliance with medication and guidelines.

J Feely1.   

Abstract

Hospitals, clinics and cardiologists have a significant impact on prescribing in general practice. Physicians in primary care rank hospital recommendations as one of the most important sources of information on new drugs. However, recent surveys of coronary heart disease (CHD) prevention paint a depressing picture about the current evidence-based management of risk factors, such as hypercholesterolaemia and hypertension, in both secondary- and primary-care settings. European guidelines have identified secondary prevention as the top priority in patients with established CHD and lowered cholesterol thresholds in light of evidence, not only from the 4S study, but also from the CARE and LIPID studies, which highlighted the risks posed by even normal or moderately elevated cholesterol levels. There is a clear need for those involved in quality assurance in hospital care to take ownership of such guidelines. Cardiologists can play a key role - they do not face the problem alone, but evidence suggests that they can have a significant positive impact on the management of CHD risk factors in primary care.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575060     DOI: 10.1016/s0021-9150(99)00253-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Practice guidelines and measurement: state-of-the-science.

Authors:  Patricia C Dykes
Journal:  Nurs Outlook       Date:  2003 Mar-Apr       Impact factor: 3.250

2.  Translating evidence into practice for providers and patients.

Authors:  Patricia C Dykes
Journal:  Evid Based Cardiovasc Med       Date:  2005-08-01

3.  Combined survival analysis of cardiac patients by a Cox PH model and a Markov chain.

Authors:  Michal Shauly; Gad Rabinowitz; Harel Gilutz; Yisrael Parmet
Journal:  Lifetime Data Anal       Date:  2011-07-07       Impact factor: 1.588

4.  The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.

Authors:  M Teeling; K Bennett; J Feely
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

5.  Under-prescribing of cardiovascular therapies for diabetes in primary care.

Authors:  K E Bennett; D Williams; J Feely
Journal:  Eur J Clin Pharmacol       Date:  2003-02-26       Impact factor: 2.953

Review 6.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

7.  A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data.

Authors:  Scott A Lear; Andrew Ignaszewski; Wolfgang Linden; Anka Brozic; Marla Kiess; John J Spinelli; P Haydn Pritchard; Jiri J Frohlich
Journal:  Curr Control Trials Cardiovasc Med       Date:  2002-11-12

8.  Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease.

Authors:  Paula Byrne; John Cullinan; Catríona Murphy; Susan M Smith
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

9.  The Return of Lombroso? Ethical Aspects of (Visions of) Preventive Forensic Screening.

Authors:  Christian Munthe; Susanna Radovic
Journal:  Public Health Ethics       Date:  2015-01-28       Impact factor: 1.940

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.